The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What difference does it make for you to know that? Do you want a breakdown of everyone's portfolio so you can short the lot?😅
I know you’re absolutely adamant that this will turn around and the share price will increase. Are you willing to say how many shares you hold here? And what share price do you hope to sell at?
If we put the numbers into something more relatable to the average person, you would see why they wouldn't care about the loss. Lets say that €850 billion is approximately £700 Billion (it is more at today's exchange rate, but for this example this assumption is fine).
If you had £70,000 in your investment portfolio, your Evg investment would be worth 5p. No investor with a portfolio worth £70k is going to give much thought to an investment worth such a small amount. So you can see why II's don't really care what price they get for an investment that, for whatever reason, they want to exit. Especially when it makes much a tiny tiny fraction of their portfolio, less than 0.00075%.
Only they will know for certain but large II's like AXA sell for many reasons. They do not have any additional information than any other investor, so have not sold due to rumours of a placement.
EVG was a minnow for them, so they really wouldn't care much for the loss they took. Assets under management of approximately €850 billion, while their holding in EVG was worth approximately £500k. It's the reason you often see II selling down at any share price in small caps like EVG, the loss to them is rather insignificant and they want out.
There have been several cases where a small cap's share price has been hammered by an II selling. only for good news to emerge in the weeks after they are fully out and the share price rockets.
They've bought property. Leasing it back to previous owners. It was in the FT this week. No big mystery. Sometimes investors change tack. Don't think any of us can pull a move like that but we might make a good return here.
You have to ask why have they decided to sell such a huge holding now? If there is a strong chance of positive news that would see this share price increase why would they not wait? They are not daft.
From the last AXA holding RNS - 13,399,724 shares held
Sell today - 25-Jan-24 09:21:08 1.55 1,074,724 Unknown* 1.50 1.60 16.66k
The stock overhang should now be gone and we no longer have a large seller lurking, we just need the RNS to confirm they are out. It looks good for the start of the re-rate.
Looks like they are out now. Delayed sell just cropped up for 1074724, shares. Matches up with the holding from AXA's last RNS. Should see a rise from here, now they are gone. Looking forward to the news flow that we are due.
Great to see. I'd expect to hear that the $500k has been paid to Evgen soon, possibly next week as they now have the funds available.
We should also hear about the application to the FDA for IND, I'd wouldn't be surprised if Stalicla try to push both STP1 & STP2 though simultaneously.
Funding news added to their website. Strengthening BOD but no names yet...
https://stalicla.com/news/press/stalicla-secures-$17.4million-in-series-b-round
Cont.
AXA selling – Can you confirm that AXA have no insider knowledge of an imminent share placement as this would be deemed insider trading.
“I confirm that we communicate with all shareholders simultaneously as is required of us by AIM rules and the UK-MAR legislation. AXA has no more information than any other shareholder.”
Juvenescence deal – Could you please confirm that Juvenescence handing back the licence to SFX-01 was solely due to their own change of business direction, as opposed to any reasons relating to SFX-01 itself. And if possible, disclose the exact wording from Juvenescence.
“Juvenescence returned the rights to us due to internal matters for them as we stated in the RNS at the time. As is best practice, the wording was agreed with them.”
Is the bod exploring a possible listing of Nasdaq or is there any current takeover talks ongoing.
“Again, as you’ll understand we can’t comment on future events but rest assured we are doing all we can to increase shareholder value in a difficult market for biotech companies. It may interest you to know that there are hundreds of Biotech companies on NASDAQ that are trading below cash. Further, Evgen is in the top 33% of all public European Biotech companies in terms of months of cash runway remaining according to a reputable London analyst group.”
These responses disprove some of the nonsense that has been posted by certain people here, who are not invested but overly emotional and irrational. We have had a better end to the week than the start and I hope we have seen the last of AXA. Next week is looking promising for the start of the re-rate and I’m looking forward to receiving the news that will be coming out soon.
I contacted shareholder relations after the release of the last RNS with a few quires for the bod and received an email back from Huw. Unfortunately, and as expected, he could not comment on a few of my questions, but he answered the ones he could. A few of these questions I wanted clarification due to the lies, miss-information and fear mongering spread by a few posters here (Kingalf and CJ).
There have been suggestions from these un-invested posters that due to the wording of the RNS, the company no longer anticipates receiving up to $5.5m in 2024 from the Stalicla partnership. Could you please confirm that the bod remains confident in the anticipation of receiving these milestone payments from Stalicla before year end (and the application of IND from the FDA).
“The language used in Tuesday’s Reach was consistent with our previous guidance on cash runway which we have always stated does not account for receipt of milestone payments. We do not incorporate milestone payments into the forecast due to their event-based nature, it would be misleading to do so when success and timing cannot be unequivocally guaranteed, this is accepted risk management practice, as well as a requirement from our auditors.”
“The milestone is event driven rather than time driven and I’m afraid we can’t comment further at this time.”
I was under the impression that the company was due to receive $0.5m on completion of the human volunteer Phase 1/1b study. As this study was completed last year, has the company received the money? If not, when is this expected to be paid (I assume imminently due to the Stalicla cash raise?) and am I correct to assume that this will extend our cash runway as it would not have been included in the bod’s figures?
“The Phase 1b milestone invoice of $500k was reflected in the half-year results released on 31st October 2023. We continue to work with our partner to deliver the payment and will provide updates when we have news to share. Future milestones are based on development activity the timeline of which is managed by Stalicla. As for Stalicla’s future fundraise activities, due to confidentiality reasons, we are not able to share further information on our partners fundraising activity over and above what they have already stated publicly.”
Several posters keep making refence to an impeding cash raise, from the issuing of a large number of shares. This includes suggesting that the bod will attempt to raise $10m from the issuing of over 660m shares, decimating existing shareholder value. While I understand a cash raise cannot be ruled out, can you confirm the bod’s intentions on cash raises and if they would/would not attempt to raise this level of cash, with the share price on its knees.
"For the reason you raise in your next question, I’m afraid we cannot comment on future events at this time, I hope you’ll understand."
Live products that no-one is buying. The CEO lied and misled investors on the sale figures, suggesting exponential growth, when the inverse is actually true. Sales tanked during the second half of the year. This is really not good for a product that is supposedly far superior to the current standard of care, and is new to the market. They are haemorrhaging cash, and this will continue for the foreseeable.
They are at the preliminary stages of 'discussions'. OBD are unlikely to see any money from these discussions this year, if at all. Cancer Research UK said last year that larger, clinical stage trails were needed for them to recommend the use of PSE v PSA and OBD have not done this.
Share price is down almost 50% in 3 days, down to 18.50p as we speak, and it is still dropping. Looking like we may see 15p next week. Investor confidence and trust is gone, and at this rate they will be lucky to raise at 10p. Really not looking good.
Maybe down but at least they have a couple of live products. It was always about finding a buyer, OBD are not set up for mass marketing and sales.
They confirmed on Wednesday that there are confidential discussions with 3rd parties.
Oh and the bods are heavily invested.
Watch this space
We just need AXA to change their mind and buy back in 😄
Most of Scandinavia seems to where I am in Thailand so I expect Toni will wait until they all go back before announcing Nasdaq First North listing... 😉
Jokes aside Stalicla do get good industry media coverage in their part of the world so I hope Toni is looking at listing Evgen there...(if it can still be done after Brexit 🤔)
Showjumper,
I hope you didn't follow Kingalf into OBD. Would be down circa 35% now.
The ironic thing is that OBD are out of cash come the end of March. With a current annual cash burn of £10m, incredibly poor sales, lack of clinical trials I can see OBD sinking much lower. Won't be surprised to see a cash raise at below 15p.
Evg on the other hand have cash till Q4, with possible milestones payments that will take this beyond 2025.
No need to panic at the red trade, it wasn't a sell 😉
I wouldn't be surprised if the terms of the Stalicla deal were revisited. Stalicla will be aware of Evgens desire to see some income and I suspect Stalicla may want to move forward but without putting a large dent in their recent funding round.
Just thunking out loud...
Weird yesterday's worked trade showing after 5pm was 440k at 1.6p the highest price paid for the day when you'd expect to see 2.5 mil worked sale at say 1.4p but nothing showed. Very positive imo, today might be the day, buyer and seller in the market now
Looks like they may finally be out. We have been seeing significant, unrelating selling during any daily rise but today we have had high volume and lots of buying. Will be interesting to see if an RNS pops up tomorrow or Monday indicating that AXA are out.
Let's hope today marks the beginning of the re-rate. I can imagine the bod may have been waiting to release news until AXA are out (if they can hold it back), as this will enable the share price to rise with very little resistance. I cannot imagine many have an average below 2.5/3p, so we should rise fairly quickly once AXA selling has dried up and the positive news flow begins.
Cleared now?? 895k strange number or could hopefully be the final piece
Thanks tricky...
I saw a website problem message on HL but managed to buy some before getting no quote again.
I picked some up yesterday so not too far of my target already
Someone on the PFC board said there's a problem with HL today DSFlatt. Good luck. Sounds like a big decision!
HL doing the same as yesterday, no quote...
That's 0.0085p
I'd wait, I can see these as low as 0.85p